ArticleACS synthetic biology2014
Engineering Escherichia coli for light-activated cytolysis of mammalian cells.
Article in ACS synthetic biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Engineered E. coli swarming for binary and analog input recording.Molecular systems biology · 2026Article
- Optogenetics for Investigating and Targeting Hallmark Traits of Cancer.Biomolecules · 2026Review
- Engineering NIR-sighted bacteria.eLife · 2025Article
- Bioengineering of bacteria for cancer immunotherapy.Nature communications · 2023Article
- Applications and Future Prospects of Micro/Nanorobots Utilizing Diverse Biological Carriers.Micromachines · 2023Review
- Engineered Cancer Targeting Microbes and Encapsulation Devices for Human Gut Microbiome Applications.Biochemistry · 2022Review
- Optogenetics: A new tool for cancer investigation and treatment.BioImpacts : BI · 2022Article
- Light-regulated gene expression in Bacteria: Fundamentals, advances, and perspectives.Frontiers in bioengineering and biotechnology · 2022Review
- Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment.International journal of molecular sciences · 2020Review
- Designing a light-activated recombinant alpha hemolysin for colorectal cancer targeting.BioImpacts : BI · 2020Article
- Blue-Light Receptors for Optogenetics.Chemical reviews · 2018Review
- Programming Bacteria With Light-Sensors and Applications in Synthetic Biology.Frontiers in microbiology · 2018Review
- Light induced expression of β-glucosidase in Escherichia coli with autolysis of cell.BMC biotechnology · 2017Article
- Engineering RGB color vision into Escherichia coli.Nature chemical biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
By delivering payloads in response to specific exogenous stimuli, smart bacterial therapeutics have the potential to overcome many limitations of conventional therapies, including poor targeting specificity and dosage control in current cancer treatments. Although not yet explored as a trigger for bacterial drug delivery, light is an ideal induction mechanism because it offers fine spatiotemporal control and is easily and safely administered. Using recent advances in optogenetics, we have engineered two strains of Escherichia coli to secrete a potent mammalian cytotoxin in response to blue or red light. The tools in this study demonstrate the initial feasibility of light-activated bacterial therapeutics for applications such as tumor cytolysis, and their modular nature should enable simple substitution of other payloads of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.